Vaccines - Kazakhstan

Kazakhstan

The Vaccines market in Kazakhstan is expected to witness a significant growth in revenue, reaching US$41.08m by 2024.
Furthermore, it is projected to display a steady annual growth rate (CAGR 2024-2029) of 0.70%, resulting in a market volume of US$42.54m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue, with an estimated value of US$29,120.00m by 2024.
Kazakhstan is experiencing a growing demand for vaccines, with a focus on immunization against infectious diseases.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Kazakhstan has been increasing steadily in recent years.

Customer preferences: Kazakhstan has a high incidence of infectious diseases, which has led to a growing demand for vaccines. The population is becoming increasingly aware of the importance of vaccination in preventing the spread of diseases, especially among children. The government has also been promoting vaccination programs to increase the immunization rate in the country.

Trends in the market: The vaccines market in Kazakhstan has been growing in recent years, driven by an increase in the number of people seeking vaccination and the introduction of new vaccines. The market is dominated by multinational pharmaceutical companies, which have a strong presence in the country. The demand for vaccines is expected to continue to grow in the coming years, driven by the government's focus on public health and the increasing awareness of the importance of vaccination.

Local special circumstances: Kazakhstan has a large rural population, which presents challenges for the delivery of vaccines. The government has been working to improve the distribution of vaccines in rural areas by setting up mobile vaccination clinics and training healthcare workers. The country also has a large migrant population, which can be difficult to reach with vaccination programs.

Underlying macroeconomic factors: Kazakhstan's economy has been growing in recent years, which has led to an increase in healthcare spending. The government has been investing in healthcare infrastructure and increasing funding for vaccination programs. The country also has a young population, which is driving demand for vaccines for children. Additionally, Kazakhstan is strategically located between Europe and Asia, making it an important market for multinational pharmaceutical companies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.